<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525915</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0703</org_study_id>
    <nct_id>NCT00525915</nct_id>
  </id_info>
  <brief_title>Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma</brief_title>
  <official_title>An Oxaliplatin-Based Phase II Randomized Study of Induction Chemotherapy Followed by Preoperative Chemoradiotherapy or Preoperative Chemoradiotherapy in Patients With Resectable Esophageal or Gastroesophageal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if a combination of the investigational
      drug oxaliplatin with 5-Fluorouracil (5-FU) (given at the same time as radiation therapy) is
      as effective as a combination of these two drugs given before and during radiation therapy in
      the treatment of esophageal or gastroesophageal cancers. The safety of these combinations of
      therapy will also be compared.

      Objectives:

      Primary objective:

      Compare the Pathologic Complete Response rate and % of patients with &lt;50% residual cancer in
      the resected surgical specimen between Arms A and B.

      Secondary objectives:

        1. Compare 1-year and 3-year survival rates, median survival time, R0 resection rates,
           safety, and local plus systemic relapse rates between Arms A and B

        2. Perform exploratory correlative studies on blood, adjacent normal and cancer tissue to
           assess predictive markers of response and outcome.

        3. Evaluate the joint effects, including possible interactive effects, of
           proton-versus-photon therapy and treatment arm on overall survival, R0 resection rates,
           safety, and local plus systemic relapse rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxaliplatin and 5-FU are chemotherapy drugs that are commonly used to treat certain kinds of
      cancers. 5-FU is designed to prevent cells from making DNA that is necessary for cell growth.
      This disrupts the growth of the cancer cells, which causes the cancer cells to start to die.
      Oxaliplatin is designed to damage DNA that is already formed.

      If you are found to be eligible to take part in this study, you will be randomly assigned (as
      in the toss of a coin) to one of two groups. Participants in the first group (Arm A) will
      receive chemotherapy with radiation treatment. Participants in the second group (Arm B) will
      receive chemotherapy first then chemotherapy with radiation treatment. The chemotherapy that
      will be used in this study includes 5-FU and oxaliplatin. Arm B is 8 weeks longer than Arm A.
      Your doctor will discuss with you whether you will receive proton or photon radiation. If you
      receive proton radiation, it will be given in a building that is about a 5 minute drive from
      the main MD Anderson radiation clinic.

      All participants will have had a routine upper gastrointestinal tract endoscopy and biopsy
      with endoscopic ultrasound examination before receiving treatment on this study. However,
      once you start on this study, the upper gastrointestinal tract endoscopy will be repeated
      before the 2nd cycle of induction chemotherapy Arm B (if needed), before chemoradiation, and
      before surgery. This procedure involves examination of the esophagus, stomach, and duodenum
      by a flexible tube. Biopsies will be taken as necessary.

      Arm A:

      If you are assigned to Arm A, you will receive treatment with 5-FU over 24 hours for 5 days
      each week for 5 weeks. It will be given as an infusion into a vein using a portable pump.
      This will start on Day 1 (Monday) and will continue until Day 5 (Friday) of each radiotherapy
      week for 5 weeks. You will need to carry this pump with you for about 96 hours. The pump is
      about the size of a personal compact disc player. You will also receive oxaliplatin as an
      infusion into a vein over 2 hours on Day 1. This will be repeated on Days 8, 15, 22, and 29.
      During this time you will receive radiation therapy every weekday for 5 weeks.

      If the cancer gets worse or you experience intolerable side effects, you will be taken off
      the study and your doctor will discuss other treatment options with you.

      Each week while you are receiving chemoradiotherapy, around 1 tablespoon of blood will be
      drawn for routine tests. Between 5-6 weeks after the completion of chemoradiotherapy, the
      stage of the cancer will be evaluated. This includes drawing blood (about 1 tablespoon) for
      routine tests, an Electrocardiography (ECG), a Physical Fitness Testing (PFT), a computed
      tomography (CT) of the abdomen and chest (when necessary), a Positron emission tomography
      (PET) or PET/CT scan, and an upper GI endoscopy with biopsies and checking the status of your
      abdominal disease (if necessary).

      When the evaluation of the status of your disease is complete, surgical removal of the
      primary tumor and lymph nodes will be attempted. All participants with no spreading disease,
      who are physically able to have surgery and have disease that is judged to be removable will
      be eligible for surgery. The tube (J-tube) will be left in your body for at least 8 weeks
      after the surgery to supplement your nutrition.

      Arm B:

      If you are assigned to Arm B, you will receive a starting (induction) course of chemotherapy
      before radiation therapy ever starts. You will receive 5-FU over 48 hours as an infusion into
      a vein using a portable pump. This will start on Day 1 and will continue over 48 hours. This
      will be repeated on Day 15 for another 48 hours. You will need to carry this pump with you at
      all times from Days 1-2 and Days 15-16. The pump is about the size of a personal compact disc
      player. You will also receive oxaliplatin as an infusion into a vein over 2 hours on Days 1
      and 15.

      One cycle is equal to 28 days, which includes 2 doses of 5-FU and oxaliplatin given on Day 1
      and Day 15. Treatment is always followed by 12 days of recovery. You will receive a maximum
      of 2 cycles (4 doses of 5-FU and oxaliplatin).

      After the first and second cycles, you will be given a full physical exam, upper GI x-rays if
      necessary, about 1 tablespoon of blood will be drawn for routine blood tests, and if needed,
      a CT scan of the abdomen and chest will be performed. You will have a PET scan or PET CT scan
      and upper GI endoscopy with biopsy (if needed) before the start of Cycle 2 and after the end
      of Cycle 2. If the disease has not gotten worse after the 1st cycle of induction
      chemotherapy, you will receive the 2nd cycle. An upper gastrointestinal tract endoscopy and
      biopsy will be performed. If the disease gets worse at any stage, you will go straight to
      chemoradiotherapy. If the disease starts to spread, you will be taken off study and your
      doctor will discuss other treatment options with you.

      You will begin to receive chemoradiotherapy no more than 12 days after you complete the last
      dose of induction chemotherapy. You will receive treatment with 5-FU over 24 hours for 5 days
      each week for 5 weeks. It will be given as an infusion into a vein using a portable pump.
      This will start on Day 1 (Monday) and will continue until Day 5 (Friday) of each radiotherapy
      week for 5 weeks. You will need to carry this pump with you at all times for about 96 hours.
      You will also receive oxaliplatin as an infusion into a vein over 2 hours on Day 1. This will
      be repeated on Days 8, 15, 22, and 29. During this time you will receive radiation therapy
      every weekday for 5 weeks.

      If the cancer gets worse or you experience intolerable side effects, you will be taken off
      the study and your doctor will discuss other treatment options with you.

      Each week while you are receiving chemoradiotherapy, around 1 tablespoon of blood will be
      drawn for routine tests. Between 5-6 weeks after the completion of chemoradiotherapy, the
      stage of the cancer will be evaluated. This includes drawing blood (about 1 tablespoon) for
      routine tests, an ECG, a PFT, a CT of the abdomen and chest (when necessary), a PET Scan or
      PET CT Scan, and an upper GI endoscopy with biopsies and checking the status of your
      abdominal disease (if necessary).

      When the evaluation of the status of your disease is complete, surgical removal of the
      primary tumor and lymph nodes will be attempted. All participants with no spreading disease,
      who are physically able to have surgery and have disease that is judged to be removable will
      be eligible for surgery. The a tube (J-tube) will be left in your body for at least 8 weeks
      after the surgery to supplement your nutrition.

      Arms A and B:

      You will be asked to fill out side effect sheets throughout your participation in this
      research study. You will be asked questions regarding nausea, hair loss, fatigue, meals, and
      other questions regarding your daily activities. You will be asked to keep a daily calendar
      while receiving therapy of any type.

      You will be asked to come for follow-up visits at MD Anderson at 3, 6, 9, and 12 months after
      surgery and then every 6 months for 2 years, and then once a year for 2 years. At these
      visits, you will have a full physical exam, and about 1 tablespoon of blood drawn for routine
      tests and a CEA test (carcinoembryonic antigen - a protein made by cancer and normal cells)
      if your CEA level was high in the past. You will also have a PET scan, PET CT scan, or CT of
      the chest and abdomen. You will have an upper GI endoscopy with biopsies 3 months after
      surgery and at other follow-up visits if needed. You may have a CT of the chest and abdomen
      at the 3 month visit if needed.

      This is an investigational study. Oxaliplatin is an investigational drug and is not approved
      in the US for use in the treatment of esophageal and gastroesophageal cancer. The combination
      of these 2 drugs (oxaliplatin + 5-FU) is investigational. All procedures are standard of
      care. A total of up to 126 patients will take part in this study. All will be enrolled at MD
      Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate</measure>
    <time_frame>Surgery post chemotherapy (approximately 10-11 weeks)</time_frame>
    <description>Pathologic Complete Response rate: percentage of participants with response reported as Pathologic complete response (pathCR) following surgery. Once surgery performed, response to therapy judged in surgical specimen with three possible categories reported: 1) Pathologic complete response (no residual cancer in the specimen); 2) &lt;50% of residual cells in the surgical specimen; or 3) &gt;50% of cells in the surgical specimen. Upon recovery from chemoradiation (Chemo), surgery follows approximately 5-6 weeks later with response assessment. Arm A schedule consists of 6 weeks of Chemo +XRT, followed by 5-6 weeks of rest, followed by surgery. Arm B schedule consist of 8 weeks of Chemo, followed by 6 weeks of Chemo +XRT, followed by 5-6 weeks of rest, followed by surgery. In particular, Arm B is 8 weeks longer than Arm A.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastroesophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Chemo with Radiation Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For 5 weeks, Chemo of 5-FU 250 mg/m^2 intravenous (IV) over 24 hours for 5 days weekly with Oxaliplatin 40 mg/m^2 IV daily over 2 hours, and Radiation treatment every weekday; then surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Pre-Op Chemo + Chemo with Radiation Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-Operative Chemo 5-FU 2.2 mg/m^2 IV continuous infusion over 48 hours start on day 1 and 15, and Oxaliplatin 100 mg/m^2 IV on day 1 and 15; followed by Surgery + Chemo with Radiation Therapy (same as Arm A)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>Arm A = 250 mg/m^2 IV over 24 hours for 5 days weekly for 5 weeks.
Arm B = 2.2 mg/m^2 IV over 48 hours on days 1 and 15.</description>
    <arm_group_label>Arm A: Chemo with Radiation Treatment</arm_group_label>
    <arm_group_label>Arm B: Pre-Op Chemo + Chemo with Radiation Treatment</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>Adrucil</other_name>
    <other_name>Efudex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Arm A: 40 mg/m^2 IV daily over 2 hours for 5 weeks
Arm B: 100 mg/m^2 IV on Day 1 and 15</description>
    <arm_group_label>Arm A: Chemo with Radiation Treatment</arm_group_label>
    <arm_group_label>Arm B: Pre-Op Chemo + Chemo with Radiation Treatment</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Radiation treatment every weekday for 5 weeks.</description>
    <arm_group_label>Arm A: Chemo with Radiation Treatment</arm_group_label>
    <arm_group_label>Arm B: Pre-Op Chemo + Chemo with Radiation Treatment</arm_group_label>
    <other_name>RT</other_name>
    <other_name>XRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.</description>
    <arm_group_label>Arm A: Chemo with Radiation Treatment</arm_group_label>
    <arm_group_label>Arm B: Pre-Op Chemo + Chemo with Radiation Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Local regional carcinoma of the thoracic esophagus (squamous cell or adeno) or
             gastroesophageal junction.

          2. Patients with T1N1, and T2-3 with any N (M1a only) will be eligible.

          3. Normal liver (serum glutamic-pyruvic transaminase (SGPT) &lt; 56µL, Total Bilirubin &lt;1.5
             mg/dL), kidney (Creatinine &lt;1.75 mg/dL), and bone marrow functions (AGN &gt;1,500µL,
             platelet count &gt;100,000/µL).

          4. Performance status 0 or 1.

          5. Signed informed consent by the investigator or their designee and patient.

          6. Medically fit for surgery.

          7. No Celiac (except for the GE junction cancers), supraclavicular, or paraaortic nodal
             enlargement unless biopsy negative.

          8. None of the celiac nodes should be larger than 2 cm

          9. Male or Female but both sexes must practice adequate contraception while on therapy

         10. &gt;/=18 years but less than 76 years

         11. No known allergy to any of the study drugs.

         12. No prior therapy for this cancer.

         13. No significant cancer (defined as non-melanomatous skin cancers and treated cervical
             cancers) within the past 5 years

         14. New York Heart Association (NYHA) I and II

        Exclusion Criteria:

          1. Patients with T1N0, T4, or M1b cancer will be excluded

          2. Significant comorbid conditions (defined as uncontrolled diabetes, active angina or
             heart failure, uncontrolled hypertension, or active psychiatric condition that
             prevents consistent participation and compliance).

          3. More than grade 1 neuropathy

          4. Unable to comprehend the requirements of the study or comply with it.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaffer Ajani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Official Website</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2007</study_first_posted>
  <results_first_submitted>January 27, 2015</results_first_submitted>
  <results_first_submitted_qc>January 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2015</results_first_posted>
  <last_update_submitted>January 27, 2015</last_update_submitted>
  <last_update_submitted_qc>January 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Gastroesophageal Cancer</keyword>
  <keyword>Gastroesophageal Junction</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>5-Fluorouracil</keyword>
  <keyword>5-FU</keyword>
  <keyword>Adrucil</keyword>
  <keyword>Efudex</keyword>
  <keyword>Oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: April 01, 2005 to June 20, 2011. All recruitment done at UT MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A: Chemo With Radiation Treatment</title>
          <description>For 5 weeks, Chemotherapy (Chemo) of 5-Fluorouracil (5-FU) 250 mg/m^2 intravenous (IV) over 24 hours for 5 days weekly with Oxaliplatin 40 mg/m^2 IV daily over 2 hours, and Radiation treatment every weekday; then surgery.</description>
        </group>
        <group group_id="P2">
          <title>Arm B: Pre-Op Chemo + Chemo With Radiation Treatment</title>
          <description>Pre-Operative Chemo 5-FU 2.2 mg/m^2 IV continuous infusion over 48 hours start on day 1 and 15, and Oxaliplatin 100 mg/m^2 IV over 2 hours on day 1 and 15; followed by Surgery + Chemo with Radiation Therapy (same as Arm A)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55">Participants who underwent surgery.</participants>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unrelated illness</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of the 126 randomized, 2 participants in Arm A declined therapy after randomization; and 13 (6 in Arm A and 7 in Arm B) experienced treatment failure before surgery leaving 55 in Arm A participants and 54 in Arm B who underwent surgery.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A: Chemo With Radiation Treatment</title>
          <description>For 5 weeks, Chemotherapy (Chemo) of 5-Fluorouracil (5-FU) 250 mg/m^2 intravenous (IV) over 24 hours for 5 days weekly with Oxaliplatin 40 mg/m^2 IV daily over 2 hours, and Radiation treatment every weekday; then surgery.</description>
        </group>
        <group group_id="B2">
          <title>Arm B: Pre-Op Chemo + Chemo With Radiation Treatment</title>
          <description>Pre-Operative Chemo 5-FU 2.2 mg/m^2 IV continuous infusion over 48 hours start on day 1 and 15, and Oxaliplatin 100 mg/m^2 IV over 2 hours on day 1 and 15; followed by Surgery + Chemo with Radiation Therapy (same as Arm A)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="30" upper_limit="74"/>
                    <measurement group_id="B2" value="60" lower_limit="27" upper_limit="75"/>
                    <measurement group_id="B3" value="60" lower_limit="27" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response Rate</title>
        <description>Pathologic Complete Response rate: percentage of participants with response reported as Pathologic complete response (pathCR) following surgery. Once surgery performed, response to therapy judged in surgical specimen with three possible categories reported: 1) Pathologic complete response (no residual cancer in the specimen); 2) &lt;50% of residual cells in the surgical specimen; or 3) &gt;50% of cells in the surgical specimen. Upon recovery from chemoradiation (Chemo), surgery follows approximately 5-6 weeks later with response assessment. Arm A schedule consists of 6 weeks of Chemo +XRT, followed by 5-6 weeks of rest, followed by surgery. Arm B schedule consist of 8 weeks of Chemo, followed by 6 weeks of Chemo +XRT, followed by 5-6 weeks of rest, followed by surgery. In particular, Arm B is 8 weeks longer than Arm A.</description>
        <time_frame>Surgery post chemotherapy (approximately 10-11 weeks)</time_frame>
        <population>Participants who had surgery were reported for the pathCR rate assessment in this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Chemo With Radiation Treatment</title>
            <description>For 5 weeks, Chemotherapy (Chemo) of 5-Fluorouracil (5-FU) 250 mg/m^2 intravenous (IV) over 24 hours for 5 days weekly with Oxaliplatin 40 mg/m^2 IV daily over 2 hours, and Radiation treatment every weekday; then surgery.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Pre-Op Chemo + Chemo With Radiation Treatment</title>
            <description>Pre-Operative Chemo 5-FU 2.2 mg/m^2 IV continuous infusion over 48 hours start on day 1 and 15, and Oxaliplatin 100 mg/m^2 IV on day 1 and 15; followed by Surgery + Chemo with Radiation Therapy (same as Arm A)</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response Rate</title>
          <description>Pathologic Complete Response rate: percentage of participants with response reported as Pathologic complete response (pathCR) following surgery. Once surgery performed, response to therapy judged in surgical specimen with three possible categories reported: 1) Pathologic complete response (no residual cancer in the specimen); 2) &lt;50% of residual cells in the surgical specimen; or 3) &gt;50% of cells in the surgical specimen. Upon recovery from chemoradiation (Chemo), surgery follows approximately 5-6 weeks later with response assessment. Arm A schedule consists of 6 weeks of Chemo +XRT, followed by 5-6 weeks of rest, followed by surgery. Arm B schedule consist of 8 weeks of Chemo, followed by 6 weeks of Chemo +XRT, followed by 5-6 weeks of rest, followed by surgery. In particular, Arm B is 8 weeks longer than Arm A.</description>
          <population>Participants who had surgery were reported for the pathCR rate assessment in this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events recorded for all participants from randomization until 30 days following last dose of study treatment (including withdrawal because of toxicity). Overall active study period was from April 2005 to July 2012.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A: Chemo With Radiation Treatment</title>
          <description>For 5 weeks, Chemotherapy (Chemo) of 5-Fluorouracil (5-FU) 250 mg/m^2 intravenous (IV) over 24 hours for 5 days weekly with Oxaliplatin 40 mg/m^2 IV daily over 2 hours, and Radiation treatment every weekday; then surgery.</description>
        </group>
        <group group_id="E2">
          <title>Arm B: Pre-Op Chemo + Chemo With Radiation Treatment</title>
          <description>Pre-Operative Chemo 5-FU 2.2 mg/m^2 IV continuous infusion over 48 hours start on day 1 and 15, and Oxaliplatin 100 mg/m^2 IV over 2 hours on day 1 and 15; followed by Surgery + Chemo with Radiation Therapy (same as Arm A)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>NAUSEA/VOMITING</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Gastrointestinal (GI) BLEED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>DYSPNEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="63"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>GRANULOCYTOPENIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="63"/>
                <counts group_id="E2" events="50" subjects_affected="50" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RED, WATERY and BURNING EYES</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="63"/>
                <counts group_id="E2" events="43" subjects_affected="43" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="63"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="63"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="63"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease (GERD)</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="63"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>MUCOSITIS</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>ESOPHAGITIS</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="63"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="54" subjects_affected="54" subjects_at_risk="63"/>
                <counts group_id="E2" events="51" subjects_affected="51" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="63"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>SUBSTERNAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>HICCUPS</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="63"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>TASTE CHANGE</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="63"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>INCREASE Alanine Aminotransferase (ALT)</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="63"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>INCREASE Aspartate Aminotransferase (AST)</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="63"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="63"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOMAGNESEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUROPATHY SENSORY</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="63"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="63"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="63"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="63"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="63"/>
                <counts group_id="E2" events="42" subjects_affected="42" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>ODYNOPHAGIA</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="63"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>SHORTNESS OF BREATH</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="63"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="63"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>SORE THROAT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS (RADIATION)</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="63"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="63"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jaffer Ajani, MD / Professor, GI Medical Oncology</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-792-2828</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

